1. Home
  2. BHB vs ERAS Comparison

BHB vs ERAS Comparison

Compare BHB & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BHB
  • ERAS
  • Stock Information
  • Founded
  • BHB 1887
  • ERAS 2018
  • Country
  • BHB United States
  • ERAS United States
  • Employees
  • BHB N/A
  • ERAS N/A
  • Industry
  • BHB Major Banks
  • ERAS Biotechnology: Pharmaceutical Preparations
  • Sector
  • BHB Finance
  • ERAS Health Care
  • Exchange
  • BHB Nasdaq
  • ERAS Nasdaq
  • Market Cap
  • BHB 558.4M
  • ERAS 448.1M
  • IPO Year
  • BHB 1997
  • ERAS 2021
  • Fundamental
  • Price
  • BHB $32.35
  • ERAS $1.41
  • Analyst Decision
  • BHB Hold
  • ERAS Strong Buy
  • Analyst Count
  • BHB 2
  • ERAS 5
  • Target Price
  • BHB $34.00
  • ERAS $5.70
  • AVG Volume (30 Days)
  • BHB 39.8K
  • ERAS 1.2M
  • Earning Date
  • BHB 04-17-2025
  • ERAS 03-26-2025
  • Dividend Yield
  • BHB 3.64%
  • ERAS N/A
  • EPS Growth
  • BHB N/A
  • ERAS N/A
  • EPS
  • BHB 2.84
  • ERAS N/A
  • Revenue
  • BHB $148,793,000.00
  • ERAS N/A
  • Revenue This Year
  • BHB N/A
  • ERAS N/A
  • Revenue Next Year
  • BHB $3.83
  • ERAS N/A
  • P/E Ratio
  • BHB $11.67
  • ERAS N/A
  • Revenue Growth
  • BHB N/A
  • ERAS N/A
  • 52 Week Low
  • BHB $23.26
  • ERAS $1.41
  • 52 Week High
  • BHB $38.47
  • ERAS $3.45
  • Technical
  • Relative Strength Index (RSI)
  • BHB 50.05
  • ERAS 25.44
  • Support Level
  • BHB $32.41
  • ERAS $1.52
  • Resistance Level
  • BHB $33.69
  • ERAS $1.76
  • Average True Range (ATR)
  • BHB 1.10
  • ERAS 0.13
  • MACD
  • BHB 0.05
  • ERAS 0.00
  • Stochastic Oscillator
  • BHB 49.68
  • ERAS 0.00

About BHB Bar Harbor Bankshares Inc.

Bar Harbor Bankshares Inc is a bank holding company along with its subsidiaries that offers a full range of financial services products, brokerage services through third-party brokerage arrangements and also trust and investment management services to individuals, businesses, non-profit organizations, and municipalities. The company has following reportable segments such as Commercial construction, Commercial real estate owner occupied and non-owner occupied, Tax Exempt, Commercial and industrial loans, Residential real estate, Home equity and Consumer other. Its products and services consist of checking, deposits, cards, mobile banking, online services, loans, merchant services, trust, and fiduciary services, investment planning, education funding, individual retirement planning..

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Share on Social Networks: